AngioDynamics Inc. filed a patent‑infringement lawsuit against Endovascular Engineering, Inc. on April 23, 2026 in the U.S. District Court for the District of Delaware. The suit alleges that Endovascular Engineering’s thrombectomy devices infringe on AngioDynamics’ patents covering its proprietary self‑expanding funnel technology used in these devices.
The filing is the first major legal action taken by AngioDynamics in 2026 and follows a settlement with C.R. Bard in April 2024 over venous access port patents. The company has a history of patent litigation, including a 2007 case against VNUS Medical Technologies and ongoing litigation over port catheters consolidated into MDL 3125. By pursuing this suit, AngioDynamics signals its commitment to defending the intellectual property that underpins its competitive advantage in the thrombectomy market.
The lawsuit could influence AngioDynamics’ financial performance if damages are awarded or if litigation costs accrue, but no specific damages have been disclosed. The company’s strategy of aggressively protecting its patents is intended to safeguard its innovation pipeline and market share, and the legal action may deter competitors from using similar technology without licensing agreements.
AngioDynamics announced a shift to a fully outsourced manufacturing model by the third quarter of fiscal 2026, a move that could affect its cost structure and production capacity for thrombectomy devices. The lawsuit’s venue in Delaware—a common forum for corporate litigation—places the case in a jurisdiction experienced with complex patent disputes in the medical device sector.
Investors will likely monitor the proceedings for potential impacts on AngioDynamics’ financial performance and market position, as the outcome could affect the company’s ability to maintain revenue growth, profitability, and competitive differentiation in the evolving vascular device landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.